Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial
Bone remodeling
Alendronic acid
Hip Fracture
N-terminal telopeptide
DOI:
10.1359/jbmr.040512
Publication Date:
2006-04-27T00:44:52Z
AUTHORS (10)
ABSTRACT
Abstract We used data from the Fracture Intervention Trial to assess relationship change in bone turnover after 1 year of alendronate or placebo treatment and subsequent hip, non-spine, spine fracture risk among 6186 postmenopausal women. In group (n = 3105), greater reductions one more biochemical marker were associated with a lower fracture. Introduction: There are few on between short-term markers non-spine bisphosphonate-treated women, clinical use such measurements is unknown. Materials Methods: measured (bone-specific alkaline phosphatase [bone ALP], intact N-terminal propeptide type I collagen, C-terminal crosslinked telopeptide collagen) BMD hip at baseline placebo. During mean follow-up 3.6 years, 72 786 336 vertebral fractures documented. Results Conclusions: Each SD reduction 1-year ALP was fewer (odds ratio 0.74; CI: 0.63, 0.87), (relative hazard [RH] 0.89; 0.78, 1.00; p < 0.050), (RH 0.61; 0.46, 0.78). Alendronate-treated women least 30% had 0.72; 0.55, 0.92) 0.26; 0.08, 0.83) relative those <30%. conclude that therapy fractures, effect as strong observed BMD.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (319)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....